Effect of luteinizing hormone-releasing hormone
analogs on the rat ovarian follicle development.
Incomplete testosterone suppression with luteinizing hormone-releasing hormone
agonists: Does it happen and does it matter?
When the procedure was assigned a quality of life weight of less than 0.83, the cost-effectiveness of luteinizing hormone-releasing hormone
was less than $50,000 per quality-adjusted life year.
Cetrorelix, a luteinizing hormone-releasing hormone
(LHRH) antagonist, had been the object of a Phase III programme in BPH, a non-cancerous enlargement of the prostate which, as reported by the company last week, did not meet its primary endpoint.
Treatment options for VUF include conservative, medical or surgical treatment.[sup.4,8,11,12] Some studies advocate conservative treatment for early diagnosed small fistula with bladder catheterization alone with antibiotics for 3 weeks.[sup.2] Others proposed induced amenorrhea by oral contraceptive pills or by luteinizing hormone-releasing hormone analog because epithelial and stromal cells that contain sex hormone receptors (as in the endometrium) had been observed within the fistula.[sup.1] This management technique may be less successful in women with a mature tract (6 weeks or longer).
Successful management of vesicouterine fistula by luteinizing hormone-releasing hormone analog.
In a personalised health care approach, the study selected patients with tumours expressing luteinizing hormone-releasing hormone
(LHRH) receptors, the key element in the targeting mechanism of AEZS-108.
Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone
agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
Pai and colleagues report a small randomized controlled trial (RCT) examining whether men who receive 6 months of neoadjuvant androgen deprivation therapy for cytoreduction recover faster whether they receive a monthly luteinizing hormone-releasing hormone
agonist (LHRHa) or an injection every 3 months.[sup.1] Unfortunately, due to accrual and eligibility issues, the authors were not able to complete the study in a timely manner and only 46 of the planned 100 patients were available for data analysis.